Press release article from our research archive:
|
|
Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan).
- Article from:
-
PR Newswire
- Article date:
-
May 30, 2008
|
Copyright informationCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN CARLOS, Calif., May 30 /PRNewswire-FirstCall/ -- Nektar Therapeutics will host a meeting and Webcast on Monday, June 2, 2008 at 6:30 PM Central Time to discuss the company's lead oncology program, NKTR-102 (PEG-irinotecan). The Webcast will include a presentation by featured speaker Dr. Daniel D. Von Hoff, M.D., F.A.C.P, the lead investigator for the NKTR-102 Phase 1 trial. Dr. Von Hoff is Physician-in-Chief and Senior Investigator at the Translational Genomics Research Institute (TGen), Chief Scientific Officer for the Scottsdale Clinical Research Institute at Scottsdale Healthcare, and Chief Scientific Officer of US Oncology.
A live audio-only Webcast of this ...
Related newspaper, magazine, and journal articles:
|
Nektar Therapeutics to Webcast R&D Day on November 12th.
PR Newswire;
October 27, 2008 ;
250 words
......PRNewswire-FirstCall/ -- Nektar Therapeutics announced that it will host...November 26, 2008. About Nektar Nektar Therapeutics is a biopharmaceutical company...jruddock@nektar.com, both of Nektar Therapeutics Web site: http://www.nektar...
|
|
|
Nektar Therapeutics to Webcast R&D Day on November 14th.
PR Newswire;
November 13, 2007 ;
262 words
......PRNewswire-FirstCall/ -- Nektar Therapeutics announced that it will host...until November 21, 2007. Nektar Therapeutics is a biopharmaceutical company...and compliance. Contact: Nektar Therapeutics, 650-631-3100, fax, 650-631-31...
|
|
|
Nektar Therapeutics President and CEO Howard W. Robin to Present at...
PR Newswire;
October 7, 2008 ;
213 words
......PRNewswire-FirstCall/ -- Nektar Therapeutics President and CEO Howard...October 27, 2008. About Nektar Nektar Therapeutics is a biopharmaceutical company...CONTACT: Stephan Herrera Nektar Therapeutics 1-415-488-7699 sherrera@nektar...
|
|
|
Nektar Therapeutics to Present at 2007 BMO Capital Markets Focus on...
PR Newswire;
November 28, 2007 ;
202 words
......PRNewswire-FirstCall/ -- Nektar Therapeutics announced today that it is...until December 19, 2007. Nektar Therapeutics is a biopharmaceutical company...CONTACT: Jennifer Ruddock of Nektar Therapeutics, +1-650-283-6253, jruddock...
|
|
|
Nektar Therapeutics' President and CEO Howard W. Robin to Present At...
PR Newswire;
January 2, 2008 ;
220 words
......PRNewswire-FirstCall/ -- Nektar Therapeutics' President and CEO Howard...replay until January 22, 2008. Nektar Therapeutics is a biopharmaceutical company...efficacy, safety and compliance. Nektar Therapeutics 201 Industrial Road San Carlos...
|
|
|
Nektar Announces Restructuring to Complete Its Transition to a...
PR Newswire;
February 12, 2008 ;
700+ words
......PRNewswire-FirstCall/ -- Nektar Therapeutics announced a restructuring...nektar.com/. About Nektar Nektar Therapeutics is a biopharmaceutical company...jruddock@nektar.com, all of Nektar Therapeutics Web site: http://www.nektar...
|
|
|
Nektar Therapeutics Issues Statement on Exubera.
PR Newswire;
October 18, 2007 ;
693 words
......PRNewswire-FirstCall/ -- Nektar Therapeutics issued a statement today...Chief Executive Officer of Nektar Therapeutics. Nektar has been very disappointed...development. About Nektar Nektar Therapeutics is a biopharmaceutical company...
|
|
|
Nektar Therapeutics Appoints Lutz Lingnau as New Board Member.
PR Newswire;
August 29, 2007 ;
695 words
......PRNewswire-FirstCall/ -- Nektar Therapeutics announced today that Mr...December 2006. About Nektar Nektar Therapeutics is a biopharmaceutical company...jruddock@nektar.com, all of Nektar Therapeutics Web site: http://www.nektar...
|
See all results.
Or, try our
Advanced Search.
|